All In Biotech

Free tool

FAERS Monitor: Latisse

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022369 or its brand name (Latisse, Bimatoprost). Reports on generic versions are filed under their own applications.

Reports

11,267

Serious

1,810

16% of reports

Hospitalization

716

Death reported

132

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective2,432
  • ocular hyperaemia1,482
  • madarosis1,369
  • eye irritation1,024
  • eye pruritus965
  • erythema of eyelid901
  • eyelids pruritus482
  • eye swelling481
  • wrong technique in product usage process454
  • wrong technique in drug usage process384
  • eyelid oedema375
  • inappropriate schedule of drug administration373
  • dry eye368
  • skin hyperpigmentation362
  • eyelid irritation337

Reports by year received

View as table
YearReports
200410
20054
20068
200712
200821
2009397
20101,527
2011886
2012513
201366
201495
20151,039
20161,023
20171,070
2018834
2019698
2020635
2021505
2022400
2023596
2024394
2025302
2026232

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,892 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
erythema of eyelidSignal901372.4347.5277,997
eyelids pruritusSignal482341.4310.3138,034
eyelid irritationSignal337289.5258.583,649
madarosisSignal1,369249.4236.5298,791
skin hyperpigmentationSignal36282.074.027,697
eyelid oedemaSignal37562.256.221,804
ocular hyperaemiaSignal1,48260.157.383,630
eye pruritusSignal96555.251.949,879
eye irritationSignal1,02433.831.932,064
eye swellingSignal48124.422.410,668
wrong technique in drug usage processSignal38419.918.16,824
dry eyeSignal36813.912.54,355
inappropriate schedule of drug administrationSignal3739.88.92,946
wrong technique in product usage processSignal4544.23.81,107
drug ineffectiveSignal2,4323.43.34,502

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.